Bacil Pharma plans ₹50 cr rights issue — equal to its entire market cap
The nano-cap pharma company with zero revenue and a market cap of ₹55 crore is raising ₹50 crore from shareholders, diluting equity by roughly 90%. Two independent directors resigned simultaneously.
— 9 earlier stories on Bacil Pharma Ltd. →What's new
- Board approved rights issue of up to ₹50 crore, matching ~91% of company's ₹55 crore market cap.
- Authorised capital raised by ₹45 crore to ₹65 crore; intermediaries appointed including monitoring agency.
- Two independent directors resigned: Dinesh Chander Notiyal and Avani Savjibhai Godhaniya.
Why this matters
For a company with trailing ROE of 1.6% and zero quarterly sales, a rights issue equal to almost the entire market cap will flood the stock with shares. The simultaneous exit of two independent directors adds governance concerns. Existing holders face severe dilution; the stock's recent insider selling suggests limited confidence even before this move.
What we're watching
- Rights issue price and entitlement ratio (determines actual dilution).
- Whether the company discloses a concrete use of proceeds.
- Any further board changes or auditor resignations.
The full read
Bacil Pharma's market cap is ₹55 crore. The company, which reported zero sales last quarter, just approved a rights issue of ₹50 crore effectively equal to its entire equity value. To accommodate the new shares, it hiked authorised capital from ₹20 crore to ₹65 crore, appointed Acuite Ratings as monitoring agency, and lost two independent directors in the same board meeting. The rights issue was a known possibility; the exact quantum and the simultaneous governance churn are new. Existing holders, already seeing insider stake sales in the past weeks (Niraj Shah sold 2.75% just last week), now face massive dilution in a stock with 36.7x trailing P/E and 1.6% ROE. The question is not whether Bacil needs money; it is what that money buys that a ₹55 crore market cap could not.
Questions answered
- How much dilution will the rights issue cause?
- If fully subscribed, the ₹50 crore issue at even a modest premium would roughly double the share count. Against a market cap of ₹55 crore, existing shareholders could see their stake diluted by nearly 50% or more, depending on the issue price.
- Why is the company raising money when it has zero revenue?
- Bacil Pharma reported no sales in the March 2026 quarter and only ₹1 crore net profit likely from other income. The rights issue appears intended to fund working capital or new initiatives, but the filing gives no specific use of proceeds.
- Why did two independent directors resign just as the rights issue was approved?
- No reason was given for the resignations of Dinesh Chander Notiyal and Avani Savjibhai Godhaniya. The timing alongside a transformative capital raise is unusual and raises questions about board comfort with the plan.
- What approvals are still pending?
- The issue is subject to regulatory (likely SEBI) and shareholder approvals. The board will determine the issue price, entitlement ratio, and record date later.
Bacil Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on BACPHAR →- 9 Jul 2026 · 8:08 PM IST Bacil Pharma plans ₹50 cr rights issue — equal to its entire market cap
- 11d ago Mumbai investor Niraj Shah buys 6.44% stake in zero-revenue Bacil Pharma
- 15d ago Bacil Pharma loses another large holder as Shah sells 2.75% stake
- 16d ago Bacil Pharma loses another big holder — Patel cuts stake by 7.10%
- 16d ago Bacil Pharma board to mull fundraising options on June 26